Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Gets New Patent For Nucleic Acid Amplification, Detection System

NEW YORK, Aug. 11 (GenomeWeb News) - Cepheid announced today the issuance of a patent covering a heating system used in its Smart Cycler and GeneXpert systems for the detection and assessment of genetic targets.


The Sunnyvale, Calf.-based company has exclusively licensed this patent from the University of California for its I-COR, or  Integrated Cooling/heating Optical Reaction system, technology.


The patent, numbered 6,602,473, specifically covers a "silicon-based sleeve type chemical reaction chamber that combines heaters...[and] combines a critical ratio of silicon and non-silicon based materials to provide the thermal properties desired."


"The reaction chamber may be utilized in any chemical reaction system for synthesis or processing of organic, inorganic, or biochemical reactions, such as the polymerase chain reaction (PCR) and/or other DNA reactions, such as the ligase chain reaction, which are examples of a synthetic, thermal-cycling-based reaction," the patent abstract reads. "The reaction chamber may also be used in synthesis instruments, particularly those for DNA amplification and synthesis."


This is the second patent the company has recently licensed for its Itechnology. In June, Cepheid licensed a patent for the optics in the I-COR system.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.